Doctors say GLP-1 therapies can transform health for some patients, but warn that rising demand for rapid cosmetic weight loss risks misuse and weakens clinical safeguards.
GLP-1 medicines have moved from diabetes clinics into the centre of a wider debate about weight loss, health and fairness. In an interview reported by India Today, diabetologist and endocrinologist Shashank Joshi argued that these drugs can be valuable when they are used for the right medical reasons, while Jitendra Choksi, founder and managing director of Fitter, warned that the trend risks turning prescription treatment into a shortcut for cosmetic goals.
The medicines, which act on a hormone involved in appetite and blood sugar control, are increasingly being used for obesity as well as type 2 diabetes. The World Health Organisation says GLP-1 therapies can help reduce appetite, improve blood sugar control and, in some patients, lower the risk of heart attack, stroke and heart failure. But the agency also stresses that they are not suitable for everyone and should be prescribed with a patient’s full medical history in mind.
That distinction lies at the heart of the disagreement described by India Today. Joshi argued that these drugs should not be reduced to vanity treatment, saying that some patients see broader health gains and may even need fewer other medicines under supervision. He pointed to people with obesity-related complications such as sleep apnoea, cardiovascular risk or kidney disease, where the aim is not simply to move the scales but to improve overall health. Healthline and MedlinePlus both note that GLP-1 medicines work by slowing stomach emptying, reducing appetite and supporting better glucose regulation, which is why they can be useful in both diabetes and weight management.
Choksi, by contrast, warned against normalising injections as a quick fix, particularly for people seeking rapid weight loss before major life events such as weddings. He also raised concerns about regulation, promotion and the possibility of misuse. The US Food and Drug Administration has separately warned about unapproved GLP-1 products being sold for weight loss, saying that patients should seek prescription medicines from licensed pharmacies and that compounded versions should be used only when approved drugs cannot meet a medical need.
The broader point is that GLP-1 treatment is neither a miracle solution nor a fad to dismiss out of hand. Consumer Reports and the American Cancer Society both note that these medicines are generally most effective when combined with nutrition, exercise and ongoing medical support, and that side effects such as nausea and vomiting can limit their use. The healthiest approach, as the India Today discussion made clear, is to treat them as one tool among many: appropriate for some patients, inappropriate for others, and never a substitute for careful clinical judgement or long-term lifestyle change.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
